Future IPO candidate

Elpiscience needs more funds for cancer research

Backed by Lilly Asia Ventures and Hillhouse, Elpiscience wants to attract more funding to develop the best-in-class solution for cancer treatment.

China-based immune-oncology company Elpiscience is currently raising Series B funding which it hopes to complete within the next couple of months.

Darren Ji, chief executive of Elpiscience, told FinanceAsia that the amount of money it is looking for will be larger than the $55 million Series A funding which it raised from Lilly Asia Ventures, Hillhouse Capital and CDH Fund in December last year. 

But the money is still not enough, according to Ji. He says that the company needs another two years fully to develop its products as Elpiscience wants to develop best-in-class treatment for the world.

Ji also...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222